Névine Zariffa is the Chair of Intelligencia AI’s Scientific Advisory Board. In this role, she provides strategic guidance on the company’s product development and roadmap while leading and coordinating the activities of the scientific advisory board.

She is a highly accomplished thought leader in the fields of biostatistics and data science with extensive experience across all phases of drug development. Most recently she served as the SVP of Biometrics and Information Sciences at AstraZeneca (AZ).

Over her 25-year pharma career, she held senior roles at GlaxoSmithKline and AZ where she also led the enterprise data & analytics initiative. She has been a key contributor to development strategies for over 200 drug projects across oncology, cardiovascular, metabolic, respiratory, inflammation, and renal diseases. Névine was a reviewer for The Lancet and has over 30 peer-reviewed publications to her name.

She is currently a strategic consultant to several organizations including scientific data consortia such as ctMoniTR. She advised the FDA, Office of the Commissioner, on the application of real-world evidence to COVID-19 and further supported COVID-19 efforts through her work at the Bill and Melinda Gates Foundation. In addition to Intelligencia AI, she currently serves on the Scientific Advisory Board of ANOVA, ZS Associates and Beaconcure. She was a board member of CDISC for six years. In 2021, she published her first novel, Sisters Pieced Together.

She holds her master of math degree in statistics from the University of Waterloo, and her bachelor of science in pure math from McGill University.

As a scientific advisor to Intelligencia AI, Aiman helps guide the organization on overall strategy and how the health tech company can help pharmaceutical organizations bring better medicines to patients, faster.   

Aiman has 25 years of experience in healthcare innovation. He is currently the managing director and CEO of a healthcare holding/investment company funded by Sheikh Fawaz Alhokair in Saudi Arabia and also serves as an adjunct professor at Georgetown University.

Previously Aiman was the Global VP for Cell and Gene Therapies at GSK, Global VP for Immuno-Oncology with AstraZeneca, VP of Global Medical Affairs at AstraZeneca, and Head of Immuno-Oncology at MedImmune. Aiman also served as the Chief Medical Officer at the Cancer Research Institute and has consulted for cancer collaborative research groups (US, EU, Asia) while also holding teaching roles in academic centers including Harvard Business School and Georgetown University. 

In the pharmaceutical industry, he has led global teams that delivered four new cancer medicines and gained approval from global regulators including the FDA, EMEA, PMDA, and sFDA generating over $2B in annual revenues. 

Aiman started his career at the National Cancer Institute (NIH), where he managed 26 cancer medicines, and was awarded by U.S. President Bill Clinton for providing early access to medicines for leukemia (Gleevec) and breast cancer (Herceptin).

Aiman holds five university degrees including two post-graduate degrees (PharmD, MBA).

In his advisor role for Intelligencia AI, Professor Gorgoulis is involved with the supervision of projects associated with drug repurposing and machine learning to evaluate molecular targets and mechanisms in oncology. He and his group have teamed up with Intelligencia AI’s bioinformatics and data science team to provide solutions that involve AI techniques in order to decipher key mechanisms in cancer biology with the main goal of discovering novel therapeutics.

Prof. Gorgoulis is a molecular pathologist who is internationally recognized in the fields of genomic instability in cancer, cellular senescence and machine learning algorithms for predicting drug response in cancer.

Currently, he is a professor and the Director of the Department of Histology – Embryology (DHE), Medical School, National and Kapodistrian University of Athens, Greece. He is also a professor and Chair of Clinical and Molecular Pathology, at Medical School, University of Dundee, UK.

Additionally, he serves as an adjunct professor in the Biomedical Research Foundation, Academy of Athens, Greece; is an honorary professor, at the Institute of Cancer Sciences, University of Manchester, UK; visiting professor, at the Faculty of Health and Medical Sciences, University of Surrey, UK; and an elected member in the European Molecular Biology Organization (EMBO).

Prof. Gorgoulis has 337 publications in international peer-reviewed journals, is listed in SCI, and has more than 30,500 citations. He has been actively involved with more than 200 speaking engagements at various international conferences, seminars, etc., and has contributed 14 chapters to international textbooks.

Prof. Gorgoulis graduated in 1988 (Summa Cum Laude) and received his PhD in 1994 (Summa Cum Laude) from the Faculty of Medicine, National Kapodistrian University of Athens. He received his Medical Specialty in Pathology (Summa Cum Laude) in 1996. 

As a scientific advisor, Dr. Tsirigos has played a pivotal role in Intelligencia AI’s development of a cutting-edge machine-learning model designed to forecast the technical and regulatory success of clinical trials. He continues to provide guidance and expertise to the growing company, leveraging his extensive knowledge and experience in machine learning and bioinformatics. 

Dr. Tsirigos is a professor of medicine and pathology at the NYU School of Medicine where he also serves as the co-director of precision medicine and director of applied bioinformatics. He leads a team of 25+ computational biologists and data scientists and his research focus is primarily on cancer epigenetics, chromatin organization, and AI-based diagnostics in cancer and other diseases.

Dr. Tsirigos has more than 20 years of experience in genomics and machine learning at NYU and IBM Research. He has co-authored more than 150 studies in peer-reviewed journals, including high-impact studies in cancer epigenetics, chromatin organization, high-throughput single-cell transcriptomic analyses, and precision diagnostics using deep learning. 

He received his doctorate in computer science from the Courant Institute of New York University and his bachelor’s from the National Technical University of Athens, Greece.

Pete Georgiadis serves as a corporate advisor to Intelligencia AI. 

He is a serial entrepreneur, experienced operator and the founder and CEO of Synetro Group, a Chicago-based private investment and strategic advisory firm. Since founding Synetro in 2000, he has led the firm’s investment in over 50 companies and has personally helped build more than a dozen software, business services and manufacturing companies, including Insurance Noodle Inc., Knowledge Advisors Inc., Kalamazoo Outdoor Gourmet, CrossCheck Compliance, Corporate Synergies Group and dScout, Inc. He currently serves as the Chairman and CEO of Pleina Group, and sits on the boards of CrossCheck Compliance and dScout, Inc.

Prior to founding Synetro, Pete was the COO of Lante Corporation, a technology consulting firm. He led the strategic repositioning and operating transformation of Lante and prepared it for a successful IPO. Before Lante, he was with McKinsey and Company, where he was a leader in the firm’s marketing and sales & channel management practices. He started his career at Hewlett-Packard Co., in marketing and general management roles in the UK and Switzerland.

Pete holds an MBA from Harvard Business School, a master’s of computer science from London’s Imperial College and a bachelor’s of science in electronic engineering from the University of Sussex. He is a committed supporter of a number of educational and social service organizations in the U.S. and Europe.

As a corporate advisor, Simo supports Intelligencia AI’s continued business growth, as the company continues to evolve and navigates various business dynamics. 

As an engineer, Simo has a passion for building products and businesses. Since 2010, he has been actively investing in and supporting the growth of a range of companies in the technology and business services industries. Serving in roles ranging from investor to board member, to an active operating team member, Simo is passionate about working with teams committed to building exceptional solutions and great companies.

Previously, Simo worked for five years as a management consultant at McKinsey where he served a broad set of financial services clients. Before that, he served as a group manager, specializing in the development of enterprise software at Oracle.

Simo holds bachelor’s and master’s degrees in electrical engineering and computer science from Massachusetts Institute of Technology, and an MBA from Harvard Business School. He is a technology enthusiast, skier, and a married father of two living near Philadelphia.

As a member of Intelligencia AI’s Scientific Advisory Board, Stephen Cho helps guide the organization on portfolio strategy, decision-making frameworks, and the application of data-driven approaches to drug development and R&D investment.

Stephen’s career spans the intersection of science, policy, and portfolio management, with more than two decades of leadership experience across pharmaceutical research, clinical development, and enterprise strategy. He currently leads the Global Portfolio & Program Management organization at BeOne Medicines.

Stephen began his career as a medicinal chemist and research project leader at Eli Lilly & Company and Pfizer before transitioning into management consulting at McKinsey & Company, where he advised leading pharmaceutical and medical technology companies on R&D strategy, portfolio optimization, and organizational effectiveness.

He subsequently joined Novartis, where he held a series of senior leadership positions spanning project management, clinical development, portfolio strategy, and enterprise governance. As Head of Portfolio Strategy & Analytics, Stephen played a central role in advancing portfolio analytics and decision-making frameworks across the organization. He led efforts to strengthen probability of technical and regulatory success (PTRS) assessments for late-stage development programs, consolidated portfolio management functions, and improved governance processes to enhance R&D efficiency, strategic alignment, and program prioritization.

Throughout his career, Stephen has championed the use of quantitative analytics and evidence-based decision-making to improve portfolio performance and resource allocation across large-scale biopharmaceutical organizations.

As a Scientific Advisor to Intelligencia AI, Stephen continues to support the company’s mission of transforming drug development through artificial intelligence, advanced analytics, and data-driven portfolio management.

As a corporate advisor, Dimitris helps guide the organization on digital transformation, artificial intelligence, data strategy, and innovation across the drug development lifecycle.

Dimitris has more than 30 years of experience spanning pharmaceutical R&D, biotechnology, healthcare technology, and data science. He currently serves as a Director at Arsenal Capital Partners, where he leads digital, data, and AI strategy initiatives across healthcare and life sciences investments.

Prior to Arsenal, Dimitris held senior leadership positions at Generate Biomedicines, Pfizer, Novartis, Covance/LabCorp, and Johnson & Johnson, where he helped drive the adoption of advanced technologies and data-driven decision-making across research and development organizations.

A recognized leader in computational science and digital innovation, Dimitris has authored more than 100 scientific publications, holds 18 U.S. patents, and is ranked among the world’s top 1% most-cited scientists. He was elected a Fellow of the Royal Society of Chemistry (FRSC) and has been recognized as one of Computerworld’s Premier 100 Technology Leaders.

Dimitris holds a PhD in Theoretical Chemistry from Imperial College London and completed postdoctoral fellowships at the University of California, Berkeley and Harvard University.

As a Scientific Advisor, Gerry brings to Intelligencia a rare combination of deep technical rigor and firsthand experience at the frontier of AI, markets, and institutional design.

Gerry is Professor of Artificial Intelligence at the University of Oxford, Deputy Dean for Human-Centered AI and Innovation, and Research Co-Director of the AI & Society Lab at the Oxford-UBS Centre for Applied AI. His research spans machine learning, algorithmic market design, and the governance of agentic systems, with a focus on how these technologies reshape markets, firms, and institutions — making him one of the most relevant voices at the intersection of AI and the industries Intelligencia serves.

His career bridges Wall Street and the academic frontier. Before joining Oxford, Gerry traded exotic derivatives at Morgan Stanley and conducted quantitative research at a hedge fund. He holds a PhD in Engineering from Stanford, trained in physics and aerospace engineering in France and at MIT, and spent nine years on the faculty of the Wharton School at the University of Pennsylvania, where he remains a Senior Fellow. He has advised leading technology companies and investors at the intersection of AI and finance, including PayPal and a16z, and was named to the Thinkers50 Radar in 2025.

As a Corporate Advisor, Jeremy brings to Intelligencia nearly three decades of experience at the intersection of healthcare, technology, data, and strategy. Through his work with high-growth healthcare companies and institutional investors, he has developed a unique perspective on how data-driven innovation is transforming life sciences, market access, and healthcare decision-making.

Jeremy is the Founder and Managing Partner of Brody Capital & Advisors (BC&A), a strategic advisory firm supporting entrepreneur-led businesses and investors across pharma technology and services, digital health, and data and analytics. Prior to founding BC&A, he served as Chief Strategy Officer at Aetion, a leading real-world evidence platform, and at Cerner Enviza, a global research and consulting organization. Earlier, at Kantar Health, he led corporate strategy and played a key role in the company’s successful acquisition by Cerner, now part of Oracle.

His career has consistently been at the forefront of healthcare innovation. Jeremy co-founded Jstreetdata.com, the first U.S. online physician market research panel, which was acquired by Interpublic Group in 2002. He began his professional journey at Covance Health Economics and Outcomes Services, helping pioneer approaches to market access and real-world evidence that have since become foundational to the life sciences industry.

Jeremy holds a Master of Science in Health Policy and Management from the Harvard School of Public Health and a Bachelor of Science from New York University. Outside of his professional work, he enjoys spending time with his wife, six sons, and two granddaughters, and produces live music events at a neighborhood café.